{"id":295313,"date":"2025-05-28T00:00:00","date_gmt":"2025-05-28T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneon0007-2023-biopharma-non-small-cell-lung-cancer-unmet-need-unmet-need-egfr-mutation-positive\/"},"modified":"2026-05-11T11:18:58","modified_gmt":"2026-05-11T11:18:58","slug":"unneon0007-2025-biopharma-non-small-cell-lung-cancer-unmet-need-unmet-need-egfr-mutation-positive-metastatic-nonsquamous","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneon0007-2025-biopharma-non-small-cell-lung-cancer-unmet-need-unmet-need-egfr-mutation-positive-metastatic-nonsquamous\/","title":{"rendered":"Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – EGFR-Mutation-Positive Metastatic Nonsquamous NSCLC (US\/EU)"},"content":{"rendered":"

Approximately 20% of nonsquamous NSCLC<\/abbr> in Western patients is driven by mutations in EGFR<\/abbr><\/em>, and as such is treated predominantly with agents targeting those alterations. The market is currently dominated by EGFR<\/abbr> TKI<\/abbr>s, including third-generation EGFR<\/abbr> TKI<\/abbr> Tagrisso (AstraZeneca), but unmet need remains for drugs offering improved survival and reduced toxicity. 2024 saw the entry into the market of new combination regimens in the first-line metastatic setting: Tagrisso plus chemotherapy; and Rybrevant plus Lazcluze (Johnson & Johnson; Yuhan). These combinations will compete with Tagrisso monotherapy, and the interplay of efficacy and tolerability attributes will be key market-share deciders.<\/p>\n

\n

QUESTIONS ANSWERED <\/strong><\/p>\n<\/div>\n

\n
    \n
  • Which attributes most influence prescribers\u2019 decisions for EGFR<\/abbr><\/em> mutation-positive metastatic nonsquamous NSCLC<\/abbr>?<\/li>\n
  • How do key current therapies, such as EGFR<\/abbr> TKI<\/abbr>s, perform on key treatment drivers and goals for this patient population?<\/li>\n
  • What are the prevailing areas of unmet need and hidden opportunities in the treatment of this patient population?<\/li>\n
  • What trade-offs across different clinical attributes and price are acceptable to surveyed medical oncologists for a hypothetical new first-line treatment for EGFR<\/abbr><\/em> mutation-positive metastatic nonsquamous NSCLC<\/abbr>?<\/li>\n<\/ul>\n<\/div>\n
    \n

    PRODUCT DESCRIPTION <\/strong><\/p>\n<\/div>\n

    \n

    Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:<\/p>\n<\/div>\n

    \n
      \n
    • Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians\u2019 weightings and analysis of stated vs. derived importance.<\/li>\n
    • Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.<\/li>\n
    • Analyze market scenarios for different target product profiles using the TPP Simulator.<\/li>\n<\/ul>\n

      Markets covered:<\/strong> United States, France, Germany, United Kingdom.<\/p>\n

      Primary research: <\/strong>Survey of 60 U.S. and 30 European medical oncologists fielded in March 2025.<\/p>\n

      Key companies:<\/strong> AstraZeneca, Boehringer Ingelheim, Cheplapharm, Pfizer, Johnson & Johnson, Roche \/ Genentech.<\/p>\n

      Key drugs:<\/strong> Tarceva, Gilotrif \/ Giotrif, Tagrisso, Rybrevant, Lazcluze.<\/p>\n<\/div>\n","protected":false},"template":"","class_list":["post-295313","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-non-small-cell-lung-cancer","biopharma-therapy-areas-solid-tumors","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295313","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295313\/revisions"}],"predecessor-version":[{"id":575782,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295313\/revisions\/575782"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=295313"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}